delolimogene mupadenorepvec

GENETIC2 trials

Sponsors

Lokon Pharma AB

Conditions

Malignant MelanomaPancreatic Cancer

Phase 1

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

CompletedNCT02705196

Lokon Pharma ABPancreatic Cancer

Start: 2016-11-01End: 2025-11-15Updated: 2026-02-24

A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma

CompletedNCT04123470

Lokon Pharma ABMalignant Melanoma

Start: 2020-01-28End: 2023-07-30Updated: 2024-09-19

Related Papers

Prior CTLA-4 blockade as associated with a hyperactive immunosuppressive signature and limited response to subsequent immunotherapy in melanoma.

Journal of Clinical Oncology2026-05-27

Abstract CT031: A phase I/II trial evaluating LOAd703 in combination with nab-paclitaxel, gemcitabine, and atezolizumab for advanced pancreatic cancer

Cancer Research2026-04-17

Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients.

2026-03-27

LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial.

2026-02-16

LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study.

2024-04-0140 citations

A phase I/II study of LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus, combined with nab-paclitaxel and gemcitabine in advanced pancreatic cancer.

Journal of Clinical Oncology2022-06-0119 citations

A phase I/II study combining a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel/gemcitabine chemotherapy in advanced pancreatic cancer: An interim report.

Journal of Clinical Oncology2020-02-0112 citations